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ABSTRACT 
 
Introduction: 
Brain tumours are the 17th most common cancer worldwide. Gliomas are the most 
common of the primary brain tumours and are highly malignant.  
 
Objectives:  
(a) To undertake gene expression profiling of the blood of glioma patients to determine 
key genetic components of signalling pathways    
(b) To develop a panel of genes that could be used as a potential blood-based biomarker 
to differentiate between high and low grade gliomas, non-glioma and control samples. 
 
Methods: 
Blood samples were obtained from glioma patients, non-glioma and control subjects. Ten 
samples each were obtained from patients with high and low grade tumours respectively, 
ten samples from non-glioma patients and twenty samples from control subjects. Total 
RNA was isolated from each sample after which first and second strand synthesis was 
performed. The resulting cRNA was then hybridized with the Agilent Whole Human 
Genome (4x44K) microarray chip according to the manufacturer's instructions. Universal 
Human Reference RNA and samples were labeled with Cy3 CTP and Cy5 CTP 
respectively. Microarray data were analyzed by Agilent Gene Spring 12.1V software 
using stringent criteria which included at least a 2-fold difference in gene expression 
between samples. Statistical analysis was performed using the unpaired student T-test 
with a p-value < 0.01. Pathway enrichment was also performed with key genes within 
these pathways selected for validation with ddPCR. 
 
Results:  
The gene expression profiling indicated that were a substantial number of genes that were 
differentially expressed with more than a 2-fold change (FDR corrected value < 0.01) 
between each of the four different conditions. We selected key genes within significant 
pathways that were analyzed through pathway enrichment. These key genes included 
regulators of cell proliferation, transcription factors, cytokines and tumour suppressor 
genes.  
 
Conclusion: 
In this study, we have shown that key genes involved in significant and well established 
pathways, could possibly be used as a potential blood-based biomarker to differentiate 
between high and low grade gliomas, non-gliomas and control samples. 
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  CHAPTER 1: INTRODUCTION 
 Cancer is the leading cause of morbidity and mortality worldwide with the 
number of cases expected to increase by 70% over the next 2 decades (1).  Brain and 
central nervous system tumours are ranked 17th in incidence among all cancers 
worldwide, being the 13th and 15th most common tumour in men and women 
respectively (2). Cancer is the 2nd leading cause of death in the paediatric age group (3), 
with brain and other nervous system tumours  ranked 2nd in incidence after leukaemias 
(4).  
 Brain tumours can be either primary or secondary. Gliomas are the most common 
of the primary brain tumours consisting  mainly of oligodendroglioma and astrocytoma 
with a small number of mixed oligoastrocytoma. Currently, there is a simple World 
Health Organization (WHO) classification for these tumours. Oligodendrogliomas are 
divided into low grade (Grade II) and anaplastic (Grade III) tumours. For astrocytic 
tumours, the WHO classification system divides this tumour into pilocytic astrocytoma  
(Grade I),  low grade diffuse astrocytoma (Grade II), anaplastic astrocytoma (Grade III) 
and glioblastoma multiforme (GBM) and its variants (Grade IV). Oligoastrocytomas are 
also classified into low grade (Grade II) and anaplastic (Grade III) tumours (5). 
  Low grade oligodendrogliomas grow slowly whereas anaplastic 
oligodendrogliomas grow more aggressively. These tumours are predominantly found in 
the cortex but may invade into other structures of the brain such as the corpus callosum, 
the ependyma and deep into the brainstem (6). 
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 Oligodendrogliomas have their own unique set of genetic alterations compared to 
other gliomas. The most common genetic alteration found in oligodendrogliomas is loss 
of heterozygosity (LOH) on chromosomes 1p and 19q (7,8). Oligodendrogliomas with 
LOH at 1p are known to be more chemosensitive than tumours with retention of this 
chromosome. In addition, combined allelic losses at 1p and 19q are associated with 
longer recurrence-free survival after chemotherapy (9). Loss of chromosome 1p is also a 
predictor of longer recurrence-free survival in patients receiving radiotherapy with or 
without chemotherapy (10,11).  
 Besides LOH on chromosomes 1p and 19q, almost all oligodendrogliomas have 
mutations in the IDH1/2 genes (12). In genome sequencing studies, IDH1 appears to be a 
persistent mutation found in all patients with low grade glioma suggesting that this 
mutation is an early event and precedes the LOH on chromosomes 1p and 19q during 
glioma development and progression (13). In addition, patients with IDH1/2 mutations 
are younger and have a more favourable prognosis compared to those without these 
mutations (14). 
 Astrocytic tumours also show many different genetic alterations. Some of the 
early genetic changes in low grade astrocytomas are mutations in IDH1 and TP53 
(15,16). In addition, there are other genomic alterations that occur as a diffuse low grade 
glioma progresses to a high grade glioma which includes the anaplastic astrocytoma and 
secondary GBM. These changes include disruption of the RB1 pathway (17), deletion of 
chromosome 9p including CDKN2A (18) and the presence of microRNAs miR-17 and 
miR-184 (19). On the other hand, primary GBM occurs de novo, has a short clinical 
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history and possesses unique genetic alterations such as EGFR amplification (20), 
EGFRvIII mutation (21), loss of the tumour suppressor gene PTEN (22) and deletion of 
chromosome 10 (23). 
   IDH1/2 mutations and MGMT promoter methylation deserve further mention as 
they have significant predictive and prognostic value in gliomas. IDH1 mutations are 
mainly found in grade II and III gliomas and secondary GBM (12). IDH2 mutations are 
commonly found in low grade oligodendrogliomas (24). Glioblastomas that have 
mutations in the IDH1 gene generally show less oedema and necrosis with reduced 
disruption of the blood brain barrier (25). VEGF is responsible for vascular permeability 
in GBM resulting in oedema, increased vascularity and tumour enhancement. HIFα 
regulates VEGF expression and is downregulated in IDH1/2 mutated cells resulting in 
tumours that have less oedema and decreased vascularity (26). In addition, tumours that 
have the IDH1/2 mutations are more sensitive to oxidative stress induced by radiation 
(27) and chemotherapy (28,29) resulting in cell death. These phenomena result in better 
prognosis for glioma patients with IDH1/2 mutations (14). 
 MGMT is a DNA repair enzyme that reverses the effects of alkylating 
chemotherapeutic agents such as temozolomide. Epigenetic silencing of the MGMT 
promoter by methylation, sensitizes GBM cells to temozolomide. The phenomenon is 
present in about half of all GBM patients resulting in marked survival when treated with 
temozolomide and radiation therapy (30). 
  The treatment for gliomas involves surgical resection, radiation and 
chemotherapy.  Maximal safe surgical resection is recommended for all patients with 
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gliomas as it results in increased survival (31). Advanced neurosurgical equipment and 
techniques such as intraoperative MRI (32) and brain mapping (33) together with the use 
of 5-aminolevulinic acid which causes fluorescence of glioma tissue (34), has increased 
safety and resulted in more extensive resections of the tumour. Despite all these 
advances, it is still not possible to achieve complete resection of the tumour as gliomas 
are diffuse and infiltrate into surrounding brain tissue. As such, the majority of glioma 
patients have to undergo adjuvant therapy in the form of radiotherapy, chemotherapy or 
both. In addition, some patients are also offered more recently available treatments such 
as targeted immunotherapy. 
 Radiation in the form of external beam irradiation is given as an adjuvant therapy 
after surgical resection for glioma patients. Radiation therapy has been shown to prolong 
survival compared to surgery alone or supportive care only (35), especially when residual 
tumour is still evident (36).  In addition to radiation therapy, chemotherapy is also used to 
treat malignant gliomas. The common chemotherapeutic agents used are procarbazine, 
CCNU and vincristine (PCV) for the treatment of oligodendroglial tumours (37,38) and 
temozolomide for the treatment of astrocytic tumours including GBM (39). Amongst 
targeted therapies for malignant gliomas, bevacizumab, a monoclonal antibody against 
vascular endothelial growth factor receptor (VEGFR) has shown promising activity (40). 
 Genome-wide characterization and classification of tumours as well as the 
development of specific inhibitors to treat such tumours, has given rise to the age of 
personalized medicine.  Bevacizumab, besides its role in the treatment of malignant 
gliomas, is also effective in treating colorectal cancer patients whose tumours harbour the 
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wild-type K-RAS oncogene (41). Approximately 25 percent of breast cancers have 
amplification of the epidermal growth factor receptor 2 gene (HER2) which is involved in 
the growth and proliferation of both normal and malignant cells and a strong driver of 
tumorigenesis (42,43). This discovery led to the development of a recombinant 
humanized monoclonal antibody, trastuzumab, which inhibits the HER2 receptor through 
antibody mediated cellular cytotoxocity (44,45). Multiple clinical trials have shown the 
superiority of using trastuzumab as an adjuvant and neoadjuvant agent in the treatment of 
early stage and metastatic breast cancers. In early stage and locally advanced breast 
cancer, the addition of trastuzumab to chemotherapy significantly improved both disease 
free survival and overall survival (46-48) whilst in metastatic breast cancer this led to 
higher response rates, prolonged time to progression and increased overall survival (44). 
 Non-small cell lung cancers, especially adenocarcinomas, have mutations in the 
intracellular tyrosine kinase domains of the epidermal growth factor receptor (EGFR) 
which results in activation of several signal transduction pathways promoting cell growth 
and proliferation (49). In addition, amplification of EGFR also promotes malignant 
transformation. Together, mutations in the tyrosine kinase domain and amplification of 
EGFR are found in 43-89 percent of cases of non-small cell carcinoma of the lung (50). 2 
oral tyrosine kinase inhibitors, gefitinib and erlotinib, have been used successfully to treat 
mutated EGFR advanced lung cancer with a response rate of 65-90 percent (51). 
 The classical case of personalized medicine and targeted therapy can be found in 
the treatment of the Philadelphia positive chromosome in chronic myeloid leukaemia 
(CML). In this myeloproliferative disorder, there is a chromosomal rearrangement 
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between the long arms of chromosomes 9 and 22, forming the Philadelphia chromosome 
(52). This translocation gives rise to a fusion protein, BCR-ABL, demonstrating 
constitutive tyrosine kinase activity (52) resulting in uncontrolled cell growth and 
proliferation (53). Imatinib mesylate (Gleevec), a potent tyrosine kinase inhibitor which 
can be taken orally, is highly effective in treating CML (54) and induces a high 
haematologic and cytogenic response (55), in addition to prolonging survival (56). 
Imatinib mesylate is also used as adjuvant treatment in localized primary gastrointestinal 
stromal tumour (GIST) where it prolongs recurrence free survival after complete 
resection of the primary tumour (57). In GIST, imatinib mesylate inhibits activation of 
the KIT proto-oncogene and the platelet-derived gowth factor receptor alpha (PDGFRα) 
(58,59). It is also used to treat metastatic GIST where it achieves partial response and 
stable disease in up to 80 percent of patients with a median survival of 5 years (60). Thus, 
personalized medicine has resulted in improved treatments and prolonged survival for 
patients with different types of cancer. 
 In the case of gliomas however, despite advances in surgery, radiation and 
chemotherapy together with more recently available therapies such as molecularly 
targeted therapies, prognosis is generally poor. The median survival for patients with 
malignant gliomas is less than 15 months with GBM patients having the worst prognosis 
with less than 5% surviving after 5 years (61).   
 One of the reasons that cancers are detected at a late stage is because many 
tumours do not have symptoms until the disease has spread. There is also poor 
compliance in adhering to standard screening procedures, as some of these tests are 
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unpleasant in nature and have associated risks and complications (62,64). The current 
methods available for the detection of gliomas are computed tomography (CT) scan and 
magnetic resonance imaging (MRI) of the brain. However, the definitive diagnosis is by 
stereotactic guided biopsy of the tumour sample which is technically demanding and has 
its risks such as causing hemorrhage, infection, seizures and neurological deficits but is 
however considered relatively acceptable (64-66). Therefore, the development of a 
simple, non-invasive blood test which involves RNA profiling in whole blood, can be 
used as an addition to the more traditional methods of cancer screening and detection 
(67). 
 The inspiration for whole-blood, transcriptome profiling in the context of gliomas 
originates from the "sentinel" principle (67). Inherent in this principle is the fact that 
blood is in intimate contact and interacts with all human tissues including cancerous 
tissue. Blood is considered a connective tissue and is a transporter for various substances 
such as oxygen, nutrients, cells of the immune system including B cells, T cells, dendritic 
and natural killer cells, cytokines, growth factors and hormones (68). In addition, blood 
cells are affected in many disease processes such as haematological malignancies, solid 
tumours, asthma, autoimmune diseases such as rheumatoid arthritis to common chronic 
illnesses such as hypertension, diabetes and cardiovascular disease (69-72). 
 Peripheral blood cells have the ability to respond to changes that affect the 
physiology, microenvironment and systems biology of the human body. Perturbations or 
disturbances in the homeostasis of the system can also be subtly detected by peripheral 
blood cells (68,73).  Thus blood, being easily accessible could serve as a molecular gene 
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expression profile reflecting changes that occur within tissues of the human body (67). 
The term "bloodomics" has thus been coined to reflect this function of blood in regulation 
of gene expression and in the molecular profiling of human diseases (68). 
 One of the earliest models where the sentinel principle has been studied is 
colorectal carcinoma where a 5 and 7-gene biomarker panel has been developed to assess 
the current relative risk of patients developing this cancer in Canada and Malaysia (74-
76). Molecular gene profiling of the blood transcriptome has also been studied in other 
diseases including neurological disorders such as schizophrenia and bipolar disorders,. 
chronic fatigue syndrome, tuberous sclerosis complex 2, neurofibromatosis type 1, 
Down's syndrome, epilepsy, Tourette syndrome, ischemic stroke, migraine, Huntington's 
and Alzheimer's diseases (77-84).   
  Genome wide expression profiling of human blood in Huntington's disease 
resulted in a 12 gene biomarker panel that was clearly able to distinguish between normal 
controls and those with Huntington's disease. In addition, the genes in this panel showed 
varying expression in disease progression from early presymptomatic to late 
presymptomatic and finally to the symptomatic stage of Huntington's disease (83). In 
acute ischaemic stroke, blood expression profiling has identified 18 genes that are 
upregulated within 24 hours of the event. These genes were found to be upregulated in 
67, 87 and 100 percent of patients after 3, 5 and 24 hours respectively (85). Some of the 
genes expressed after 3 hours are involved in the inflammatory process such as MMP9 
and also participate in the degradation of the extracellular matrix and breakdown of the 
blood brain barrier. MMP9 is mainly secreted by neutrophils (86) and levels correlate 
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with infarct volume and hemorrhagic complications after thrombolytic therapy (87-89). 
S100 proteins are also released during acute ischaemia (90) bind to the vascular 
endothelium and induce a thrombotic state (91). These early changes in the expression 
levels of certain genes in blood, can be exploited as a diagnostic and predictive tool for 
acute stroke. Blood expression profiling in migraine has been able to distinguish between 
migraine and chronic migraine with a group of immediate early genes such as c-fos and 
cox-2 being upregulated in migraine while specific mitochondrial genes were upregulated 
in chronic migraine (92).  
 Epilepsy in children treated with carbamezepine or valproic acid showed distinct 
patterns of expression in blood. In addition, patients treated with valproic acid formed 
distinct subclusters of those who were responsive versus refractory to treatment (81). 
Blood based gene expression has also been studied in schizophrenia and bipolar disorder. 
A set of putative biomarker genes to differentiate between schizophrenia and bipolar 
disorder has been validated with an accuracy of 95-97 percent by receiver operating 
characteristic (ROC) curve analysis (77). As can be seen, personalized medicine is 
revolutionizing the field of neurology including diseases with a pure brain pathology. 
 However, results obtained from gene expression profiling in blood have to be 
interpreted with caution.  In colorectal carcinoma, the 7-gene biomarker panel assesses 
the current relative risk of a person developing the disease compared to the general 
population according to a scale (74). The panel of genes only indicates the probability of 
developing the disease and there is some overlap between high risk and low risk 
populations (75). 
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 In Huntington's disease (HD), 4 of the 12 genes in the biomarker panel were 
upregulated in the Affymetrix platform but downregulated in the Amersham Biosciences 
platform (83). The reason for the discrepancy in results was most likely due to the probes 
on the different platforms hybridizing to different isoforms of the gene (83). This is 
clearly one of the drawbacks of gene expression profiling in blood unless custom made 
arrays are used where probes are specifically designed to detect all relevant exons. 
 Although gene expression profiling in blood has been undertaken in ischaemic 
stroke patients (85), the results need to be evaluated further. This is because all the 
patients in the study were treated with either tissue plasminogen activator (tPA) or tPA 
and eptifibatide. Thus, the increase in the number of genes that were upregulated after 3 
hours could have been partly due to a direct effect of these medications on gene 
expression in blood.  
 Similarly for the psychiatric disorders, schizophrenia and bipolar disorder, the 
results of the studies have to be viewed critically, as all patients were receiving 
medications (77). It is likely that these medications, including antipsychotics and mood 
stabilizers, alter the gene expression profile in blood directly and therefore account for 
the differences seen. In addition the sample size was small and consisted of 30 patients 
with schizophrenia, 16 patients with bipolar disorder and 28 healthy control subjects (77) 
and has not been replicated in the literature to date. 
 Nonetheless given the accessibility of blood and the totality of available data on 
"bloodomics", blood-based profiling to differentiate between gliomas remains a 
promising approach. Furthermore, in considering cancers, there are compelling biological 
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reasons to believe that this may be a useful approach. It is known that during 
development of a tumour, substances are secreted by the tumour into the bloodstream and 
as a systemic response, there are subtle alterations in the level of expression of genes 
within peripheral blood cells in order to maintain homeostasis or as a reaction to the 
disease entity itself (67). Disruption of the blood-brain barrier is due to loss of substances 
such as the tight junction proteins claudin-1 and claudin-3, decrease in polarity of glioma 
cells, loss of the molecule agrin and upregulation of the aqueous channel protein, 
aquaporin 4 (AQP4) resulting in brain oedema formation (93-99). Since blood-brain 
barrier disruption occurs in brain tumours (100,101), substances that play a role in both 
homeostasis and tumourigenesis are likely to be secreted into the bloodstream under such 
conditions and may give a molecular profile signature.  
 In addition, cells may dislodge from the tumour and enter the peripheral 
circulation as circulating tumour cells (CTCs). These CTCs then colonise a distant tissue 
or organ and begin to form a new tumour mass. Although most CTCs do not survive in 
the circulation, a subset of cells known as disseminated tumour cells (DTCs) that have 
cancer stem cell properties are able to survive. These DTCs initially undergo an 
epithelial-to-mesenchymal transition (EMT), enter the circulation and then re-express 
their epithelial properties through the process of mesenchymal-to-epithelial transition 
(MET). They are then able to invade a distant tissue or organ site and form tumour cell 
clusters known as micrometastasis (102). 
 Since CTCs are found in extremely low levels in the circulation (less than 5 cells 
per 10mL of blood)(103), identification and detection of these cells require analytical 
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methods that are highly sensitive and specific combined with enrichment procedures. 
Among the procedures used for enrichment of CTCs are density gradient centrifugation, 
immunomagnetic procedures and filtration (102). Immunomagnetic procedures generally 
involve antibodies directed against tumour-associated antigens especially the epithelial 
cell adhesion molecule (EpCAM)(104) for positive selection or the common leukocyte 
antigen CD45 for negative selection(102). 
  EpCAM is found only on epithelial cells and therefore DTCs may be missed as 
they do not express this marker (105). CTCs have been extensively studied in tumours of 
epithelial origin such as breast, colon and prostate cancer including global gene 
expression profiling of CTCs of these tumours (106).  CTCs have also been detected in 
patients with gliomas particularly those patients with high grade tumours such as GBM. 
However, glioma cells do not express EpCAM but instead express Nestin, both in, in 
vitro and in vivo studies. This suggests that Nestin could be used as a suitable marker for 
the detection of circulating glioma cells. In addition, glioma cells also express high levels 
of human telomerase (hTERT) which co-localizes with Nestin in vivo (107). 
 Detection of CTCs in glioma patients also has clinical utility. Many glioma 
patients who have undergo chemoradiaton therapy have necrosis of brain tissue which 
shows a persistence of signal on MRI. Clinicians are unable to accurately determine 
whether such signals are due to disease progression or pseudoprogression as current 
imaging (CT and MRI) cannot distinguish between them (107). However, the  
identification of glioma-derived CTCs in the circulation of such patients posttreatment is 
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prognostic, with a reduction in CTCs indicating treatment response and an increase in 
CTCs indicating disease progression (107). 
  As mentioned earlier, the prognosis for gliomas remains poor and has not 
changed much since the 1980s, despite advances in neuroimaging, neurosurgery, 
chemotherapy, radiotherapy and targeted therapy. It has been shown that patient survival 
depends on several clinical and biological factors such as tumour size and location (108), 
age at presentation (109), treatment (110,111), Karnofsky performance score (KPS)(112), 
histology (113), and molecular genetics of the tumour (114). 
 In this study, we have extrapolated the fascinating theory of the sentinel principle 
to the development of adult gliomas and to determine if such expression profiling in 
blood could be used to distinguish between high and low grade gliomas, non-gliomas and 
control samples. The justification for  this study is that such profiling will help not only 
in the stratification of gliomas, but also in the early detection of tumours when they are 
far more amenable to complete surgical resection, thus improving prognosis and survival 
of the patient. 
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WHO Grade 
 
Astrocytic 
Tumours 
 
Oligodendroglial 
Tumours 
 
Mixed Gliomas 
I Pilocytic 
Astrocytoma 
_ 
 
_ 
II Low Grade Diffuse 
Astrocytoma 
Oligodendroglioma Oligoastrocytoma 
III Anaplastic 
Astrocytoma 
Anaplastic 
Oligodendroglioma 
Anaplastic 
Oligoastrocytoma 
IV Glioblastoma 
Multiforme 
_ _ 
 
Table 1: World Health Organization (WHO) classification of gliomas 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Clinical patient data 
 Upon admission to the hospital, demographic data and a brief clinical history was 
elicited from 30 of the 50 patients. The demographic data included the age and sex of the 
patient and the state in which the patient was domiciled. The 30 patients comprised of 10 
high grade gliomas (HG), 10 low grade gliomas (LG) (Table 2) and 10 non-glioma (NG) 
cases (Table 3). The remaining 20 subjects were normal, healthy controls (C) (Table 4) 
Due to the limited availability of samples, we were unable to fully age and sex match 
patients. The summary statistics for all 4 groups of patients is shown in Table 5.  
 The clinical history centered on whether there was a past history of brain tumours 
or other cancers in the family or the patient. In addition, patients were asked about any 
neurological symptoms they experienced prior to admission to the hospital, such as 
headache, nausea or vomiting, seizure, personality changes, slurring of speech, changes 
in vision or sensation and motor changes (Table 6). This data was documented on a 
patient consent form.  
 Informed consent was obtained prior to blood taking and brain tumour removal 
from the patient during surgery. The consent was obtained from the patient or a close 
relative the day before surgery. After obtaining consent, blood was immediately drawn 
from the patient. Surgery was performed the next day, typically within 12-24 hours of 
obtaining consent and drawing blood from the patient. The patient's consent was also 
obtained in order to perform further analysis and studies on the extracted samples. In 
addition, this study had received ethics approval from the Medical Research Ethics 
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Committee (MREC) of the Ministry of Health, Malaysia. The ethics approval reference 
was KKM/NIHSEC/08/0804/P10-622. Ethics approval for this project (NMRR-10-930-
7461) was given on 24
th
 January 2011 and was valid through 16
th
 January 2015.  A 
schematic diagram showing the process of blood collection, study design and procedure 
is shown in Figure 1.  
2.2 Histopathological examination 
 Brain tumour tissue was sectioned onto glass slides and stained with 
haematoxylin and eosin (H&E). The slides were read by neuropathologists at the 
respective hospital. The diagnosis was made based on the World Health Organization 
(WHO) classification of tumours of the central nervous system (2007) (5). Of the 20 
tumour samples, 10 each were high and low grade gliomas respectively (Table 1). Grade 
I and II tumours were classified as low grade while Grade III and IV tumours were 
classified as high grade. The incidence of gliomas is 2-3 new cases per 100,000 
population per year (115). As such, the number of samples we were able to collect on our 
own was small. 
2.3 Non-glioma and control samples 
 In addition to the 20 tumour samples, 10 non-glioma and 20 control samples were 
also obtained. The 10 non-glioma cases constituted patients with an inflammatory, non-
malignant condition of the brain and included cases of hemangioblastoma, haemorrhagic 
and ischaemic stroke, inflammatory pseudotumour, arteriovenous malformation and 
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multiple sclerosis (Table 2). The 20 control subjects were healthy with no known illness 
(Table 3).  
2.4 Blood sample collection 
 2.5ml of venous blood was drawn from each patient using the BD Vacutainer 
(Becton Dickinson, USA) with attached 21G x 3/4" x 12" butterfly needle directly into 
the PreAnalytiX (PAXgene) Blood RNA Tube (BRT) (Qiagen, Germany). The samples 
were kept at room temperature for 2 hours to allow for complete lysis of cell components 
after which they were stored at -20
0
C. 
2.5 RNA extraction 
  RNA was extracted from each blood sample using the PreAnalytiX (PAXgene)
TM
 
Total RNA Blood Extraction Kit (Qiagen, Germany). After collection, the blood sample 
in the PAXgene Blood RNA Tube (BRT) was incubated at a minimum of 2 hours at room 
temperature to ensure complete lysis of blood cells. The BRT was then spun for 10 
minutes at 3000-5000 x g. The supernatant was removed and the pellet containing the 
blood cells vortexed until dissolved in 4 ml of RNase- free water. The BRT was 
centrifuged again and the supernatant removed. 350µl of resuspension buffer  was added 
and the pellet vortexed until dissolved. The sample was transferred into a 1.5ml 
microcentrifuge tube where 300µl of binding buffer was added to bind the RNA   which 
was predominantly derived from leukocytes. 40µl of proteinase was also added to 
dissolve any protein present in the sample. The lysate was transferred directly into a 
PAXgene Shredder spin column and centrifuged to remove cell debris. The flow through 
 32 
 
supernatant containing the total RNA was mixed with 350µl of 96-100% ethanol and 
vortexed. 700µl of the sample was pipetted into the PAXgene RNA spin column to which 
DNase I was added to remove any contaminating DNA. The PAXgene RNA spin  column 
was washed several times with wash buffers 1 and 2 after which 40µl of elution buffer 
was added directly onto the PAXgene RNA spin column membrane. This was 
centrifuged for 1 minute at 8000-20,000 x g to elute the RNA. The eluate containing the 
total RNA was incubated at 65
0
C for 5 minutes and then chilled immediately on ice. 
 The concentration and purity of the RNA was analyzed using the 
Spectrophotometer NanoDrop ND1000 (Thermoscientific, USA). The integrity of the 
RNA was analyzed using the Agilent 2100 BioAnalyzer RNA 6000 Nano Chip platform 
(Agilent Technologies, USA). The  concentration of RNA obtained ranged from 37 to 
442 ng/µl. The average value for the RNA Integrity Number (RIN) for the samples was 
7.4 with a standard deviation of 0.87.  The samples were stored at -80
0
C until further use. 
2.6 Microarray processing 
 Two-colour microarray-based gene expression utilizing the Agilent 4x44K whole 
human genome microarray, was performed on RNA isolated from the 50 blood samples. 
This array was chosen because it contained all the known genes in the human genome 
and was readily available at a competitive price.  Standard protocols were followed for 
sample preparation, probe labelling and hybridization according to the Two-Colour 
Microarray-Based Gene Expression Analysis Protocol (Agilent Technologies, USA).  
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 For sample preparation, the Two-Colour RNA Spike-In kit (Agilent 
Technologies, USA) was used. Spike A and Spike B Mix were thawed, mixed vigorously 
on a vortex mixer and then heated at 37
0
C in a water bath for 5 minutes. 3 serial dilutions 
of 1:20, 1:40 and 1:4 were performed for each spike mix. For the labelling reactions, the 
Low Input Quick Amp Labelling Kit (Agilent Technologies, USA) was used. 150ng of 
total RNA to a volume of 1.5µl was labelled.  2µl of the Spike A Mix/Cy3-CTP  was 
used to label the Universal Human Reference RNA (Stratagene,  USA) while 2µl of the 
Spike B/Cy5-CTP was used to label the HG, LG, NG and C samples respectively. 1.8µl 
of T7 Promoter Primer Mix (consisting of 0.8µl T7 promoter primer and 1µl nuclease-
free water) was added to the reaction containing 3.5µl of total RNA and diluted RNA 
spike-in mix. The primer and template were denatured by incubating the reaction in a 
water bath at 65
0
C for 10 minutes. The reactions were then placed on ice for 5 minutes. 
4.7µl of cDNA master mix (2µl 5X first strand buffer, 1µl 0.1M DTT, 0.5µl 10mM 
dNTP and 1.2µl AffinityScript RNase block mix) was added to each sample tube to a 
total volume of 10µl. Samples were incubated at 40
0
C in a water bath for 2 hours after 
which they were moved to a 70
0
C water bath and incubated for a further 15 minutes. The 
samples were then incubated on ice for 5 minutes. Finally, 6µl of transcription master 
mix (0.75µl nuclease-free water, 3.2µl 5X transcription buffer, 0.6µl 0.1M DTT, 1µl 
NTP mix, 0.21µl T7 RNA polymerase blend and 0.24µl Cy3-CTP/Cy5-CTP) was added 
to each sample tube for a total volume of 16µl and incubated at 40
0
C in a water bath for 2 
hours.                                                                                                                                                                                                                                                   
 The resulting labelled/amplified cRNA was purified as per protocol using the 
RNeasy mini spin columns (Qiagen, Germany). The cleaned cRNA sample was eluted by 
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transferring the RNeasy column to a new 1.5ml collection tube. 30µl RNase-free water 
was added directly onto the RNeasy filter membrane and allowed to stand for 60 seconds. 
The RNeasy column in the collection tube was then centrifuged at 4
0
C for 30 seconds at 
13,000rpm. The flow-through containing the cRNA sample was maintained on ice. If not 
used immediately, the samples were stored at -80
0
C.  
 The cRNA was quantified using the Nanodrop spectrophotometer as described 
previously. The yield and specific activity of each reaction was determined respectively 
as follows: 
(Concentration of cRNA)  x 30µl (elution volume)  =  µg of  cRNA 
   1000 
 
Concentration of Cy3 or Cy5     x 1000  =  pmol Cy3 or Cy5 per µg cRNA 
Concentration of cRNA 
  
For the 4-pack microarray format, almost all yields obtained were ≥ 0.825µg and had 
specific activity (pmol Cy3 or Cy5 per µg cRNA) ≥ 6.    
 The initial step for the hybridization reactions involved the fragmentation of 
RNA. For the 4-pack microarray format, 825ng each of Cy3- and Cy5-labelled, linearly 
amplified cRNA, 11µl of 10x blocking agent were made up to a volume of 52.8µl with 
nuclease free water, after which 2.2µl of 25x fragmentation buffer was added to a total 
volume of 55µl. The samples were incubated at 60
0
C for exactly 30 minutes to fragment 
the RNA and then immediately cooled on ice for 1 minute. 55µl of the fragmentation mix 
containing cRNA was mixed with an equal volume of 2x GE hybridization buffer HI-
RPM. The samples were spun in a microcentrifuge at 13,000 rpm for 1 minute at room 
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temperature to drive any residual sample from the walls and lid of the tubes and to help 
with bubble reduction. The samples were then placed on ice and loaded onto the array 
immediately. 100µl of sample was pipetted into the gasket slide well of the Agilent 
SureHyb chamber and the "active side" of the array placed directly on top of the gasket 
slide to form a sandwich pair. The SureHyb chamber cover was placed on the 
sandwiched slides and the clamp assembly tightened onto the chamber. The assembled 
slide chamber was then placed in a rotisserie hybridization oven at 20rpm and the 
samples allowed to hybridize at 65
0
C for 17 hours. The slides were then washed with 
Gene Expression Wash Buffer 1 followed by Prewarm Gene Expression Wash Buffer 2. 
In addition, 0.0005% Triton X-102 was added to both buffers which reduced the 
possibility of array wash artifacts. The microarray slides were scanned using the DNA 
Microarray Scanner (Agilent Technologies, USA). 
2.7 Data extraction  
 Data was extracted using Agilent feature extraction software analyzed with Gene 
Spring version GX 12.5V (Agilent Technologies, USA). The data files were extracted in 
text (.txt) format after Lowess normalization. The sequence of events involved in 
processing of the data files were as follows: thresholding, summarization, dye swap, ratio 
computation, log transformation and baseline transformation.   
 Thresholding involved a substitution step where all expression values below a 
certain specified value were made constant. Thresholding was done to remove very small 
expression values or negative values in the dataset. This was to ensure that there were no 
very large negative numbers when the data was log transformed. Summarization was 
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done by calculating the geometric mean of the expression values. Raw signal values were 
then generated which essentially were linear data that had undergone thresholding and 
summarization for the individual channels (Cy3 and Cy5). Normalized signal values refer 
to the data after it has undergone ratio computation, log2 transformation and baseline 
transformation. Normalization was also done using the Human Reference RNA. 
 Dye-swapping accounts for dye related bias as different dyes (Cy3 and Cy5) bind 
DNA with different affinities. This dye related bias cannot be removed by standard 
normalization methods. In GeneSpring, samples that have been marked as dye-swapped 
were treated as follows: Cy3 was designated as "signal" and Cy5 as "control" and the 
signal was computed as Cy3/Cy5. For samples that have not undergone dye-swapping, 
GeneSpring treats Cy5 as "signal" and Cy3 as "control" and the signal is computed as 
Cy5/Cy3.   
 In baseline transformation, the baseline to median of control samples was 
performed. In the Agilent 4x44K Human Array, there are a set of samples designated as 
controls that can be used for all samples. In this baseline transformation, for each probe, 
the median of the log summarized values from the control samples was first computed, 
after which, this value was subtracted from the sample.  
 As mentioned previously, Lowess normalization was performed before the raw 
data was extracted. Lowess normalization is critical for reducing intra-array (within slide) 
variation. In 2 colour experiments, 2 fluorescent dyes, red and green, are used. The 
intensity-dependent variation in dye bias may introduce spurious variations in the dataset. 
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Lowess normalization is performed which merges the 2 colour data and applies a 
smoothing adjustment which removes such variations. 
2.8 Investigating the effects of tumour status, age, gender and experimental array 
batch on gene expression 
A linear mixed regression analysis was performed using the “R” statistical 
package, to investigate the effects of tumour pathology, age, gender and experimental 
batch effects on gene expression. The tumour status was defined by the four groups of 
samples, HG, LG, NG and C. The age and gender of patients are represented in Tables 2, 
3 and 4. Samples were run on arrays in 4 experimental batches as follows: Batch 1: 6 HG 
and 6 LG samples, Batch 2: 4 HG, 4 LG and 4C samples, Batch 3: 8C and 4 NG samples, 
Batch 4: 8C and 6 NG samples. The explanatory power of each factor was assessed in a 
stepwise manner by examining the increase in the variation explained when a new 
covariate or set of covariates was added to the existing model. This resulted in the 
investigation of the following four models: 
(1) Model 1:  Gene expression as a function of tumour status 
(2) Model 2:  Gene expression as a function of tumour status and age 
(3) Model 3:  Gene expression as a function of tumour status, age and gender  
(4) Model 4:  Gene expression as a function of tumour status, age, gender and 
array batch 
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In total there were 50 microarray samples each with 29,092 gene expression 
values from 44,000 probe sets. In preparation of input data for multiple regression 
analysis, a table of 50 microarray samples (50 rows) x 29,092 gene expression values 
(29,092 columns) was generated. The metadata for each sample that included tumour 
status, age, gender and array batch were combined as columns in the prepared table. The 
input data was then read into the “R” software. For each gene, a linear model was fitted 
using the Im() function to its respective gene expression values versus variable(s) of 
interest as per the four models. For each model, there were 29,092 r
2 
(coefficient of 
determination) values that were generated. Each r
2
 value was then modified to generate 
an adjusted r
2
 value to account for the number of variables and the sample size. A 
median, mean and range for r
2
 was then calculated for each model as shown in Figure 2 
and Table 7. 
 2.9 Unsupervised hierarchical clustering 
 Unsupervised hierarchical clustering using the Euclidean distance method and 
Ward's linkage was performed on each of the 4 different pairs of conditions and all 4 
conditions.  
 One of the limitations in unsupervised hierarchical clustering is that this form of 
analysis could be influenced by noise and outliers particularly when sample sizes are 
small. 
2.10 Principal component analysis (PCA) 
 Principal component analysis (PCA) was performed on the complete data set. The 
first step in PCA was to subtract the mean from each of the data dimensions. Then, the 
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covariance matrix and the eigenvectors and eigenvalues of the covariance matrix were 
calculated. Data compression and reduced dimensionality was performed when 
converting the data into components and to form feature vectors in 3 dimensions along 
the x, y and z axis.  
 2.11 Identification of significant differences in gene expression between the 4 
different conditions 
 The moderated t-test, a modification of the Student’s t-test, was used to identify 
significant differences in gene expression between the 4 sets of conditions (HG vs C, LG 
vs C, HG vs LG and NG vs C). While the Student’s t-test calculates variance from the 
data that is available for each gene, the moderated t-test uses information from all of the 
genes to calculate variance. This is particularly useful when a small number of samples is 
available in each group (as in this case) making the variance estimates unstable. 
 When testing was performed across these different conditions, each gene was 
considered independently from the other as a moderated t-test was performed on each 
gene separately. Given that in this microarray experiment, the expression levels of 44,000 
probes was measured simultaneously across each condition, multiple testing correction 
(MTC) was required. MTC is performed to control for occurrence of false positives that 
arise as a result of performing multiple tests. The purpose of MTC is to keep the overall 
error rate (false positive rate) to less than the p-value cutoff as specified by the user, even 
if hundreds or thousands of genes are being analysed. With this in mind, the Benjamini 
and Hochberg (B-H) false discovery rate was used to control for the large number of tests 
performed. This procedure is one of the less stringent methods of MTC but it provides a 
 40 
 
good balance between identification of many genes that are statistically significant and 
protection against false positives (type I error). 
 The B-H multiple-testing correction of p-values was chosen because it is widely 
used, relatively easy to implement and computationally inexpensive. However, the B-H 
corrected p-values may be slightly over-corrected as the p-value decreases because they 
involve the upper boundary of the false discovery rate. This corresponds to the case 
where the null hypothesis is true for all tests. In addition, null distributions for the 
different tests are assumed to be independent which may not be the case. 
2.12 Pathway analysis 
 For each group, genes were selected based on at least a 2-fold difference in 
expression and a B-H corrected p-value <0.01. Pathway analysis was performed using the 
Ingenuity Pathway Analysis (IPA) programme (Johns Hopkins University, Baltimore, 
Maryland, USA). 
 IPA is based on the Ingenuity Knowledge Base. In IPA, canonical pathways are 
well characterized pathways that have been curated and hand-drawn by PhD level 
scientists and the information comes from specific journal articles, review articles, text 
books, and Human Cyc, an encyclopaedia of human genes and metabolism 
(http://humancyc.org). Gene selection for the canonical pathways is based on this 
analysis. Although IPA is a single database, it is built upon a large collection of resources 
and the Ingenuity Knowledge base is one of the largest repositories in the world. It 
includes information from many databases such as the Biomolecular Interaction Network 
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Database (BIND), Biological General Repository for Interaction Databases (BIOGRID), 
ClinicalTrials.gov, Cognia, Database of Interacdting proteins (DIP), Gene Ontology 
(GO), GVK Biosciences, HumanCyc, Ingenuity Expert Findings, Ingenuity ExpertAssist 
Findings, INTACT, Interactome studies, Molecular Interaction Database (MINT), 
Munich Information Centre for Protein Sequences (MIPS), and microRNA database 
(miRBase). Furthermore, the IPA database is updated weekly. One drawback is that some 
very well established curated pathway databases are not included in IPA such as KEGG 
and REACTOME. Ideally, an analysis should be run against all canonical pathway 
databases. However, there is a very high level of overlap between many of these pathway 
databases. 
2.13 Fisher’s Exact Test and p-values 
 For a given gene list and pathway, the p-value associated with a pathway is a 
measure of its statistical significance in relation to the genes or pathway annotation for 
the gene list and a Reference Set of genes, which is defined by the total number of genes 
that could possibly be involved in all the pathways. The p-value for the pathways was 
calculated using the right-tailed Fischer’s Exact Test. 
 In the right-tailed Fischer’s Exact Test, only the over-represented functions or 
pathways will be shown. Under-represented functions or pathways (left-tailed p-values) 
will not be shown. Due to the large number of pathways tested, multiple testing 
correction (MTC) was performed using the Benjamini-Hochberg false discovery rate 
(FDR) with a corrected p-value <0.05. In some cases, the supporting evidence was further 
explored to grasp a better understanding of the biological significance. 
 
 42 
 
2.14  cDNA synthesis 
 RNA from each sample was converted to cDNA using the high capacity RNA-to-
cDNA kit (Applied Biosystems, USA). This kit used the reverse transcriptase enzyme 
from the multiscribe murine leukaemia virus (MuLV) mixed with RNase inhibitor 
protein. Optimal blend priming was performed with a mixture of random octamers and 
oligo dT primers. 
 200ng of total RNA was mixed with 10.0 µl of 2x Reverse Transcriptase (RT) 
buffer, 1.0 µl 20X enzyme mix and nuclease-free water to a total volume of 20.0 µl. The 
tube containing the reaction mix was then incubated in the T-Professional basic 
thermocycler (Biometra, Germany) at 37
0
C for 60 minutes after which the reaction was 
terminated by heating to 95
0
C for 5 minutes. The reactions were then used for droplet 
digital PCR (ddPCR) or stored long-term at -80
0
C. 
2.15 Droplet digital polymerase chain reaction (ddPCR) 
  Selected genes (Table 12 under Results section) from each of the 4 group pairs as 
mentioned previously, were verified using ddPCR. Reactions for each sample were done 
either singly or in duplicate. Beta- glucuronidase (GUSB) was used as the  reference gene 
as it showed the least variation with gene expression amongst the other housekeeping 
genes used, namely TATA binding protein (TBP) and human acidic ribosomal protein 
(HuPO). All reagents and equipment used for ddPCR were from Bio-Rad, USA. 10ng of 
cDNA was mixed with 10 µl of 2x ddPCR Supermix for Probes (No dUTP), 1 µl 20x 
target primers/probe mix (FAM) or 20x reference primers/probe (HEX) and nuclease-free 
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water to a total reaction volume of 20 µl. The entire reaction mix of 20 µl was then 
loaded into a sample well of a DG8 Cartridge for the QX200/QX100 Droplet Generator. 
This was then followed by adding 70 µl of Droplet Generation Oil for Probes into the oil 
wells of the cartridge, according to the QX200/QX100 Droplet Generator Instruction 
Manual. The cartridge was then inserted into the Automated Droplet Generator. After 
droplet generation, the droplets were transferred to a 96-well plate and then sealed with 
foil using the PX1 PCR Plate Sealer. 
 Thermal cycling was then performed on the droplets using the C1000 Touch 
Thermal Cycler with 96-Deep Well Reaction Module according to the following 
protocol: enzyme activation at 95
0
C for 10 minutes (1 cycle), denaturation at 94
0
C for 30 
seconds followed by annealing/extension at 55
0
C for 1 minute (40 cycles), enzyme 
deactivation at 98
0
C for 10 minutes (1 cycle) followed by hold at 4
0
C. The ramp rate was 
set at 2
0
C/sec, the heated lid to 105
0
C and the sample volume at 40µl. After thermal 
cycling, the sealed plate was placed in a QX200/QX100 Droplet Reader and the absolute 
gene expression level per well for the probes and reference genes were quantitated using 
the QuantaSoft Software. 
 For analysis of the gene expression data, we assumed a normal distribution. Each 
gene was evaluated for its expression in a minimum of 3 to a maximum of 6 samples 
under each pair of conditions. The gene expression values for each sample were 
normalized to the housekeeping gene.  The values for the absolute level of gene 
expression as obtained by ddPCR were then subjected to the t-test for the genes selected 
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under the 4 sets of conditions, with a resulting fold change and p-value. Statistical 
outliers were removed using the box and whisker plot.  
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Histopathology Grade Age Gender 
Pilocytic astrocytoma 
 
I 31 Male 
Diffuse astrocytoma 
 
II 17 Male 
Diffuse astrocytoma 
 
II 32 Male 
Fibrillary astrocytoma 
 
II 62 Female  
Recurrent astrocytoma 
 
II 45 Female 
Diffuse astrocytoma 
 
II 36 Male 
Low grade astrocytoma 
 
II 59 Male 
Low grade oligodendroglioma 
 
II 45 Male 
Low grade oligodendroglioma 
 
II 56 Male 
Recurrent oligodendroglioma 
 
II 59 Male 
Anaplastic oligoastrocytoma 
 
III 37 Female 
Anaplastic oligoastrocytoma 
 
III 58 Male 
Recurrent anaplastic 
oligoastrocytoma 
 
III 66 Male 
Anaplastic astrocytoma 
 
III 29 Female 
Anaplastic astrocytoma 
 
III 43 Male 
Glioblastoma multiforme 
 
IV 24 Male 
Glioblastoma multiforme 
 
IV 54 Male 
Glioblatoma multiforme 
 
IV 24 Male 
Glioblastoma multiforme 
 
IV 34 Male 
Glioblastoma multiforme 
 
IV 56 Female 
 
Table 2: WHO classification, histopathology of tumour samples and demographic 
data 
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Patient 
no 
Age Gender Sample Type 
1 40 Male Hemangioblastoma 
2 77 Male Blood Clot 
3 44 Female Inflammatory pseudotumour 
4 27 Male Arteriovenous malformation 
(AVM) 
5 51 Female Ischaemic stroke 
6 53 Female Hemangioblastoma 
7 61 Male Haemorrhagic stroke 
8 56 Female Multiple sclerosis 
9 34 Female Ischaemic stroke 
10 46 Female Haemorrhagic stroke 
 
Table 3: Demographics and types of non-glioma samples 
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Patient no. Age Gender 
1 30 Female 
2 38 Female 
3 41 Male 
4 57 Male 
5 25 Male 
6 57 Male 
7 33 Male 
8 51 Male 
9 28 Male 
10 25 Male 
11 56 Male 
12 32 Male 
13 22 Male 
14 59 Female 
15 42 Female 
16 55 Male 
17 58 Male 
18 48 Male 
19 33 Male 
20 55 Male 
 
Table 4: Demographics of control samples 
 
 
 48 
 
Patient/Subject 
type 
 No. of 
patients/subjects 
Male Female Age 
range 
(years) 
 
Median 
age 
(years) 
Low Grade 
Glioma 
10 8 2 17-62 45 
High Grade 
Glioma 
10 7 3 24-66 40 
Non-glioma 10 4 6 27-77 48.5 
Control 20 16 4 22-59 41.5 
 
Table 5: Summary statistics of patients 
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Question Information requested 
1 Patients were asked if there was any history of brain tumours or other 
cancers in the family. 
 
2 Patients were asked if they had any of the following neurological 
symptoms prior to presenting to the hospital: 
(a) Headaches     (b) Seizures    (c) Personality changes    (d) Slurring of 
speech 
(e) Changes in vision    (f) Changes in sensation     (g) Motor weakness 
(h) Other symptoms such as vomiting 
 
 
Table 6: Questionnaire 
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Figure 1: Schematic diagram of blood collection, study design and procedures 
 
 
 
 
 
 
 
 
 
 
Consent obtained from patients at respective 
hospital 
5ml  of blood drawn from patient into PAX Gene 
RNA tube 
 
PAX Gene RNA tube kept on ice and transported 
within 30 minutes to laboratory, kept at room 
temperature for 2 hours to allow complete lysis 
of cell components 
Total RNA extracted from PAX Gene RNA 
tube. If RNA not extracted immediately, 
samples stored at -80
0
C 
Total RNA converted to cDNA and hybridized 
with Agilent 4x44K whole human genome 
microarray; results analyzed 
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CHAPTER 3: RESULTS 
 
3.1 Modelling the effects of tumour status, age, gender and experimental array 
batch effects on gene expression 
Using a linear mixed regression analysis, the effect of tumour pathology, age, 
gender and experimental batch on gene expression was investigated. For models 1, 2, 3, 
and 4, the median and mean adjusted r
2 
values did not vary significantly (Table 7, Figure 
2). The change in median values for models 2 and 3 were 0.0077% and 0.0065% 
respectively as compared to model 1, suggesting that age and gender had a minimal 
impact on gene expression globally. For model 4, the change in the median adjusted r
2
 
value when compared to tumour status alone was 3.57%, indicating that array batch had 
some impact on gene expression globally, but that this was still small. The mean adjusted 
r
2 
values showed a similar trend. Based on these findings, all subsequent analysis focused 
on the impact of tumour pathology alone on gene expression. 
3.2 (a) Microarray analysis of samples 
  Unsupervised hierarchical clustering was performed on each of the 4 different 
pairs of conditions (HG vs C, LG vs C, HG vs LG and NG vs C) and all 4 conditions 
together, with the total gene input list, using the Euclidean distance method and Ward's 
linkage. The gene input list consisted of genes which were found to be differentially 
expressed with a corrected p-value < 0.01 and a fold change of at least 2. The results are 
shown in Figures 3(a-e).  All the microarray analysis heat maps clearly showed the 
different groups clustering independently. This was seen clearly in the unsupervised 
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hierarchical clustering with all four conditions together which showed that there were 3 
clusters of samples: one cluster for the high grade tumours, a second cluster for the low 
grade tumours and a third cluster for the non-glioma and control samples. In Figure 3(e), 
the non-glioma and controls clustered together and were distinct from the glioma 
samples, with the low grade glioma being furthest from the control and non-glioma 
samples. Therefore, not only were we able to show a distinction between the glioma and 
control samples but were also able to distinguish between high and low grade gliomas. 
(b) Principal component analysis (PCA) of samples 
  The PCA plot (Figure 4) of the first 3 axes, showed results that were very similar 
to that of the microarray analysis, demonstrating clear separation into the 3 clusters of 
samples as mentioned in 3.2(a). Of specific note, is that the 2 sample types which were 
closest to each other were the control and non-glioma sets. 
 
3.3 Volcano plots 
 Multiple testing correction using the Benjamini-Hochberg (B-H) analysis with a 
corrected p value of  <0.01, and a two-fold change cut-off,  for each of the four 
conditions were as follows: HG vs C: total number of genes: 1055, with 479 upregulated 
and 576 downregulated; LG vs C: total number of genes: 2708, with 713 upregulated and 
1995 downregulated; HG vs LG: total number of genes: 1629, with 1287 upregulated and 
342 downregulated; and NG vs C: total number of genes: 82, with 56 upregulated and 26 
downregulated (Table 8). The results were represented on volcano plots [Figures 5(a)-
(d)].  
 53 
 
 The results showed that there were relatively few genes which were differentially 
expressed between control and non-glioma samples. In comparing the glioma samples to 
the controls, the predominant effect was the downregulation of genes in the glioma 
samples. When comparing the high and low grade samples, there was in general an 
upregulation occurring in the high grade samples. 
 
3.4 Venn Diagram of Differentially Expressed Genes 
 The Venn Diagram represented the genes with at least a 2 fold difference in 
expression and a p-value <0.01, that were unique to each condition and also those that 
overlapped between the various conditions (Figure 6). There were 104 genes common to 
both the HG vs C and the HG vs LG pairs. These included genes belonging to the zinc 
finger transcription factor, ZNF 649 and ZNF 205, homeobox genes such as HOXB2 and 
SOX8, a transcription factor involved in embryonic development and determination of 
cell fate. For the HG vs LG pair, there were a total of 1629 genes, of which 644 were 
unique to this pair and included EGFR, TGFβ1 and VEGFA. There were 573 genes 
common to both the HG vs C and LG vs C pairs. These common genes included 
IL12RB1, FOS, TP53 and TNF. One important gene common to the HG vs C, LG vs C 
and HG vs LG pairs was IL6.  
 For the NG vs C pair, there were 46 unique genes, 19 that overlapped with the HG 
vs C pair, 7 that overlapped with the LG vs C pair and another 7 that were common to the 
HG vs LG and LG vs C pairs. There were no genes common to all 4 conditions (Figure 
6).  
 
 54 
 
3.5 Canonical Pathways  
  The significance of association between differentially expressed genes and the 
canonical pathways (as annotated by the HumanCyc Pathway Database) were assumed to 
follow a normal distribution and assessed using the B-H multiple testing correction to 
calculate a p-value. Only those pathways with a corrected p-value <0.05 were selected. 
This determined the probability that the association between the genes and the pathways, 
relative to all functionally characterized human genes, were not explained by chance 
alone [Figure 7(a)-(d)]. The IPA also determines whether the pathways are activated or 
inhibited by assigning a z score. The ratio defined the proportion of differentially 
expressed genes from a pathway to the total number of genes that make up that particular 
pathway. For the HG vs C pair, 4 significant pathways were identified (ratios ranging 
from 0.084 to 0.136) with no evidence for significant activation or inhibition as shown by 
z scores close to zero. (Figure 7a). The 4 significant pathways included those involved in 
innate and adaptive immunity. For the LG vs C pair, the IPA predicted a mixed pattern of 
activity for the 46 significant pathways with 23 pathways having no activity pattern 
available, 5 pathways having a positive z-score (predicted activation), 16 pathways 
having a negative z-score (predicted inhibition) and 2 pathways having a z-score of zero 
(Figure 7b). The z-score of zero corresponded to the standard mean of the normal 
distribution curve. Pathways having no activity pattern available meant that a z-score 
could not be calculated. The significant pathways with a positive z-score included those 
involved in LXR/RXR activation, RhoG, Ephrin B, IL-8 and cholecystokinin/gastrin-
mediated signalling. The z-score of zero included pathways involved in NF-κB activation 
by viruses and glioma invasiveness signalling. The significant pathways with a negative 
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z-score were signalling by the Rho family of GTPases, Tec kinase signalling, HGF, 
eicosanoid, integrin, acute phase response, PEDF and thrombin signalling. It also 
included pathways involved in PKC, actin nucleation and immune system signalling. 
 For the HG vs LG glioma pair, 9 significant pathways were predicted with 6 
having no activity pattern and 1 each with a positive, negative and zero z-score 
respectively. The activity pattern referred to the differential expression of genes that 
made up the pathway.  The 6 pathways with no activity pattern were those involved in 
FXR/RXR activation, superoxide radical degeneration, hepatic fibrosis/hepatic stellate cell 
activation, role of tissue factor in cancer, clathrin-mediated endocytosis and 
atherosclerosis signalling. The pathways that had a positive z-score, a z-score of zero and 
a negative z-score were pathways involved in LXR/RXR activation, coagulation system 
and acute phase response signalling respectively (Figure 7c). For the NG vs C pair, there 
was only one significant pathway, hepatic fibrosis/hepatic stellate cell activation that had 
no activity pattern available (Figure 7d). 
 In summary, the total number of pathways with differentially expressed genes for 
each pair of conditions after B-H multiple testing correction, is shown in Table 9. The list 
of pathways are listed in Table 10. In Tables 11(a)-(d), the significant pathways are 
shown for each pair of conditions together with the B-H multiple testing correction value 
and associated genes. 
 
3.6 Venn Diagram of Significant Pathways 
 The Venn diagram for the pathways showed pathways that were unique to each 
pair of conditions and also pathways that overlapped between the 4 different groups 
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(Figure 8). For the HG vs C pair, there was 1 unique pathway and 3 pathways that 
overlapped with the LG vs C pair.. The LG vs C pair had 39 unique pathways. The 
pathways that overlapped between the HG vs C and LG vs C pairs were pathways 
involved in the innate and adaptive immune response. The HG vs LG pair had a total of 9 
significant pathways, with 4 unique pathways, 4 overlapping with the LG vs C pair and 1 
overlapping with the NG vs C pair. The 4 unique pathways were the superoxide radicals 
degradation, clathrin-mediated endocytosis, coagulation system and role of tissue factor 
in cancer pathways. The 4 pathways overlapping with the LG vs C pair were the acute 
phase response, FXR/RXR activation, LXR/RXR activation and atherosclerosis signalling 
pathways. The 1 pathway overlapping with the NG vs C pair was the hepatic 
fibrosis/hepatic stellate cell activation pathway (Figure 8). 
 
3.7 Heat Map 
 A heat map (Figure 9) with genes commonly involved in tumour signalling 
pathways especially in high and low grade brain tumours was generated with the four 
types of samples, namely C, NG, LG and HG glioma respectively.   The results showed a 
unique differential pattern of expression for each of the 4 sample types. In addition, genes 
commonly upregulated in high grade tumours such as EGFR and VEGFC, are also highly 
expressed in blood. On the other hand, these genes are downregulated in the low grade 
tumour heat map. Specific isoforms of Bcl2 such as Bcl2L11 and Bcl2A1 are upregulated 
in the low grade but not high grade samples.  None of the genes involved in 
tumourigenesis are significantly upregulated in the non-glioma and control samples. 
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3.8 Genes Chosen for Validation by ddPCR 
 10 genes were selected for statistical validation by ddPCR (Table 12).  These 
genes were selected from the list of differentially expressed genes that were significant 
from the 4 pairs of conditions. These genes were selected because they were known to be 
common genes involved in pathways related to tumourigenesis including the 
pathogenesis of brain tumours. Only the NG vs C had no significant genes that were 
downregulated. The other 3 conditions had significant genes that were both upregulated 
and downregulated. 
 Each gene was evaluated for its expression in a minimum of 3 to a maximum of 6 
samples under each pair of conditions. The values for the absolute level of gene 
expression as obtained by ddPCR was then subjected to statistical analysis. A normal 
distribution of the values was assumed and the t-test applied to each gene with a resulting 
p-value. 7 of the 10 genes had p-values <0.05 and 3 genes had p-values >0.05. The genes 
with a p-value <0.05 were MMP, MAP3K8, TP53, SOS1, FOS, IL6 and TNF. The genes 
with a p-value >0.05 were EGFR, VEGFA and MAPK12 (Table 12). Multiple testing 
correction of the p-value using the Bonferroni correction with a threshold p-value of 0.05 
and 10 test samples, resulted in only 4 genes that were highly significant. The genes were 
MAP3K8, TP53, SOS1 and IL6 (Table 13). 
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Figure 3 (A)-(E): Unsupervised hierarchical clustering of the different conditions by 
use of the Euclidean similarity measure and Wards linkage to visualize variation in 
gene expression between the selected conditions: (A) HG vs C, (B) LG vs C, (C) HG 
vs LG, (D) NG vs C and (E) all 4 conditons together. The heat map showed the gene 
expression for the different conditions in columns, with a dendogram representing 
their similarity. The clustering was performed on a filtered gene list of normalized 
signal intensity values (averaged over replicates) for each condition. 
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Figure 3(a): Unsupervised hierarchical clustering of HG  vs C samples. 
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Figure 3(b): Unsupervised hierarchical clustering of LG vs C samples 
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Figure 3(c): Unsupervised hierarchical clustering of HG vs LG samples 
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Figure 3(d): Unsupervised hierarchical clustering of NG vs C samples
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Figure 3(e): Unsupervised hierarchical clustering of all 4 condition pairs 
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Figure 4: Principal Component Analysis (PCA) plots for the different conditions. 
Panels (A) - (C) are plots based on the first 3 principal components in various 
orientations. The axes corresponds to principal component 1 (PC1, x-axis), PC2 (y-
axis) and PC3 (z-axis). Panel D is a plot of PC axes 1 and 2.  The ellipses (2 standard 
deviation coverage; see colour key for the different conditions) showed a distinct 
directionality in the different groups based on similarities in gene expression.  
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Figure 4: Principal Component Analysis (PCA) plots in various orientations for all 4  
conditions together. 
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Figure 5: Volcano plots to determine differentially expressed genes for the 
individual pairs of conditions: (A) HG vs C, (B) LG vs C, (C) HG vs LG, and (D) 
NG vs C. The x-axis represents the log2 fold change of genes for the different 
condition pairs, while the y-axis represents the -log10 of the corrected p-values for 
the different pairs of conditions. Each dot represents a gene and the red coloured 
area represents the differentially expressed genes that meet the selection criteria of a 
fold change (FC) of at least 2 (FC≥ 2 or ≤ 2) and a p-value <0.01. 
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Figure 5: Volcano plots showing differentially expressed genes for the individual 
pairs of conditions: (A) HG vs C; (B) LG vs C; (C) HG vs LG ; (D) NG vs C. 
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Figure 6: Venn diagram of differentially expressed genes for the different condition 
pairs. The Venn diagram summarizes the number of distinct and overlapping 
differentially expressed genes found in the four condition pairs: HG vs C (Gene List 
1), LG vs C (Gene List 2), NG vs C (Gene List 3), and HG vs LG (Gene List 4). 
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Figure 7: Canonical pathways with corrected B-H p-value <0.05 identified by IPA 
for the four different condition pairs: (A) HG vs C, (B) LG vs C, (C) HG vs LG and 
(D) NG vs C. The significant pathways are shown along the x-axis of the bar charts. 
The ratio defined the proportion of differentially expressed genes from a pathway 
related to the total number of genes that make up that particular pathway (line 
graph, z-axis). The height of the bar represents the -log (B-H corrected p-value). 
The orange colour bar indicates a positive z-score (predicted activation), the blue 
colour bar indicates a negative z-score (predicted inhibition), the grey colour bar 
indicates no predicted activity and the white bar was given a z-score of zero. Colour 
intensity indicates prediction confidence (light to dark represents less to more 
confidence). 
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Figure 7(A): Canonical pathways with corrected B-H p-value <0.05 as identified by 
IPA for the HG vs C pair. 
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Figure 7(B): Canonical pathways with corrected B-H p-value <0.05 as identified by 
IPA for the LG vs C pair 
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Figure 7(C): Canonical pathways with corrected B-H p-value <0.05 identified by 
IPA for the HG vs LG pair. 
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Figure 7 (D): Canonical pathways with corrected B-H p-value <0.05 identified by 
IPA for the NG vs C pair. 
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Figure 8: Venn diagram of canonical pathways. The Venn diagram summarizes the 
number of distinct and overlapping pathways found in the 4 condition pairs: HG vs 
C (Pathway List 1), LG vs C (Pathway List 2), NG vs C (Pathway List 3), and HG vs 
LG (Pathway List 4). 
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Figure 9: Heat Map of selected differentially expressed genes for the 4 different 
conditions. 
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Model Median Mean 
1 0.11830 0.17220 
2 0.110700 0.163200 
3 0.11180 0.16360 
4 0.1540 0.1882 
 
Table 7: Median and mean adjusted r
2
 values for models 1-4 
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Condition HG vs C LG vs C HG vs LG NG vs C 
Total no. of 
genes 
 
1055 2708 1629 82 
Upregulated 
genes 
 
479 713 1287 56 
Downregulated 
genes 
 
576 1995 342 26 
 
Table 8:  Summary list of significant differentially expressed genes for the 4 pairs of 
conditions 
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 HG vs C 
HG vs 
LG 
LG vs C NG vs C 
Total number of pathways 4 9 46 1 
 
Table 9. No. of significant pathways for each pair of conditions with a corrected B-H 
p-value of <0.05 
 
 
 
Table 10: List of pathways with a corrected B-H p-value <0.05 for the 4 condition 
pairs: (A) HG vs C, (B) HG vs LG, (C) LG vs C and (D) NG vs C 
 HG vs 
C 
HG vs 
LG 
LG vs 
C 
NG vs 
C 
Actin Nucleation by ARP-WASP Complex   ✓  
Acute Phase Response Signaling  ✓ ✓  
Agranulocyte Adhesion and Diapedesis   ✓  
Allograft Rejection Signaling   ✓  
Altered T Cell and B Cell Signaling in 
Rheumatoid Arthritis 
✓  ✓  
Atherosclerosis Signaling  ✓ ✓  
B Cell Development   ✓  
CCR5 Signaling in Macrophages   ✓  
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Cholecystokinin/Gastrin-mediated Signaling   ✓  
Clathrin-mediated Endocytosis Signaling  ✓   
Coagulation System  ✓   
Communication between Innate and Adaptive 
Immune Response Cells 
✓  ✓  
Crosstalk between Dendritic Cells and 
Natural Killer Cells 
✓  ✓  
Cytotoxic T Lymphocyte-mediated Apoptosis 
of Target Cells 
  ✓  
Dendritic Cell Maturation   ✓  
Eicosanoid Signaling   ✓  
Ephrin B Signaling   ✓  
FXR/RXR Activation  ✓ ✓  
Germ Cell-Sertoli Cell Junction Signaling   ✓  
Glioma Invasiveness Signaling   ✓  
Graft-versus-Host Disease Signaling   ✓  
Granulocyte Adhesion and Diapedesis   ✓  
Granzyme A Signaling   ✓  
Hepatic Fibrosis / Hepatic Stellate Cell 
Activation 
 ✓  ✓ 
HGF Signaling   ✓  
IL-8 Signaling   ✓  
IL-12 Signaling and Production in 
Macrophages 
  ✓  
IL-17A Signaling in Airway Cells   ✓  
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Integrin Signaling   ✓  
LXR/RXR Activation  ✓ ✓  
MSP-RON Signaling Pathway   ✓  
NF-κB Activation by Viruses   ✓  
OX40 Signaling Pathway   ✓  
PEDF Signaling   ✓  
PKCθ Signaling in T Lymphocytes   ✓  
Primary Immunodeficiency Signaling   ✓  
Production of Nitric Oxide and Reactive 
Oxygen Species in Marcrophages 
  ✓  
Reelin Signaling in Neurons   ✓  
Regulation of Actin-based Motility by Rho   ✓  
RhoGDI Signaling   ✓  
Role of IL-17A in Psoriasis   ✓  
Role of Macrophages, Fibroblast and 
Endothelial Cells in Rheumatoid Arthritis 
✓    
Role of NFAT in Regulation of the Immune 
Response 
  ✓  
Role of Tissue Factor in Cancer  ✓   
Sertoli Cell-Sertoli Cell Junction Signaling   ✓  
Signaling by Rho Family GTPases   ✓  
Small Cell Lung Cancer Signaling   ✓  
Superoxide Radicals Degradation  ✓   
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Tec Kinase Signaling   ✓  
TGF-β Signaling   ✓  
T Helper Cell Differentiation   ✓  
Thrombin Signaling   ✓  
 
 
 
 
Table 11. Detailed list of pathways with corrected B-H p-value <0.05 and with 
significant differentially expressed genes for the 4 pairs of conditions. 
Table 11(A): HG vs C 
Ingenuity Canonical 
Pathways 
-log(B-H p-
value) 
Genes 
Role of Macrophages, 
Fibroblasts and Endothelial 
Cells in Rheumatoid Arthritis 
1.72E00 CAMK4, FZD3, PRSS2, IL6R, CEBPD, 
PIK3R5TLR8, IL17RC, FZD9, IGHG1, IL6, 
IRAK3, IL1R1, CEBPE, FOS, TLR10, 
WNT10A, LEF1, TLR3, TNF, TNFSF13B, 
PRSS3, WNT5A, TRAF1 
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 
1.72E00 TLR10, HLA-DOA, SLAMF1, PRTN3, 
TLR8, CD79A, IL, TLR3, TNFRSF13C, 
TNF, TNFSF13B 
Crosstalk between Dendritic 
Cells and Natural Killer Cells 
1.52E00 HLA-G, KIR3DL1, PRF1, KIR2DL2, 
FSCN2, NCR3, KIR2DL4, IL6, TLR3,TNF, 
ITGAL 
Communication between 
Innate and Adaptive Immune 
Cells 
1.32E00 HLA-G, TLR10, CCL4, TLR8, IGHG1, 
IL6,TLR3,TNFRSF13C, TNF, TNFSF13B 
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Table 11(B): LG vs C 
Ingenuity Canonical 
Pathways 
-log(B-H p-
value) 
Genes 
Atherosclerosis Signaling 1.82E00 APOE, CCR3, ABHD3, COL2A1, ALOX12, 
CCR2, IL6, NFKB2, IL1F10, SAA4, 
PLA2G2A, ALOXE3, ITGB2, COL1A1, 
ALB,IL18, ALOX15B, PLA2G4D, TGFB, 
SERPINA1, S100A8, TNF, RBP4, APOC3 
IL-12 Signaling and 
Production in Macrophages 
1.82E00 APOE, IL12RB1, MAF,  PIK3R5, MST1, 
ALOX12, TGFB1, SERPINA1, S100A8, 
NFKBIB, PRKD1, PPARG, NFKB2, 
MAPK12, SAA4, PIK3R3, FOS, ALB, IL18, 
PIK3R6, MAP3K8, MST1R, TNF, APOC3, 
RBP4 
OX40 Signaling Pathway 1.82E00 B2M, HLA-DOA, TNFRSF4, CD3E, CD4, 
NFKB2, MAPK12, BCL2, CD3G, HLA-
DRB1, HLA-DQB2, FCER1G, HLA-DOB, 
NFKBIB 
Signaling by Rho Family 
GTPases 
1.82E00 CDC42EP5, GNA11, PIK3R5, GNG13, 
ARHGEF1, LIMK1, MAP3K10, CDH7, 
ITGA3, GNB3, PPP1R12B, GNA15, RHOU, 
MRAS, PIP5KL1, CDH13, RND2, SEPT14, 
CFL1, RHOC, ARPC5L, ARHGEF15, 
ITGA2, GNAI1, WASF1, NFKB2, GNAZ, 
MAPK12,MYL9,PIK3R3, FOS, RHOV, 
PIP5K1C, WAS, NCF2, PIK3R6, SEPT6 
LXR/RXR Activation 1.82E00 APOE,ABCG5, NR1H4, C9, SERPINF,1 
IL6NFKB2, IL1F10, SAA4, SERPINF2, 
HPR,IL18, ALB, CD14, S100A8, 
SERPINA1, NCOR1, PTGS2RXRB, TNF, 
AGT, RBP4, APOC3 
Tec Kinase Signaling 1.82E00 GNA11, PIK3R5, GNG13, ITGA3, GNB3, 
GNA15, RHOU, MRAS, TNFRSF10A, 
PRKD1, RND2, STAT5A, RHOC, ITGA2, 
GNAI1, BMX, GNAZ, NFKB2, MAPK12, 
PIK3R3, FOS, RHOV, WAS, VAV3, 
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FCER1G, PIK3R, TNF 
Granulocyte Adhesion and 
Diapedesis 
1.82E00 CLDN11, SELL, IL1F10, CXCL5, CLDN7, 
ITGB3, ITGA3, CLDN4, CCL3L3, CXCL1, 
CLDN9, CLDN10, HRH2, C5AR1, MMP28, 
ITGA2, GNAI1, ITGAL, ITGB2, CXCL16, 
IL18, CLDN5, CCL4, CXCL2, CX3CL1, 
TNF, CLDN3, HSPB1 
Primary Immunodeficiency 
Signaling 
1.82E00 IL7R, IL2RG, AIRE, CD3E, CD4, IGKC, 
IGLL1/IGLL5, ICOS, RAG1, CD79A, 
IGHG1, TNFRSF13C 
B Cell Development 1.82E00 IL7R,HLA-DOA,HLADRB1,CD79B, IGKC, 
CD86,HLA-DOB, RAG1,CD79A 
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 
1.82E00 HLA-DOA, SLAMF1, CD79B, CD79A, IL6, 
IL1F10, NFKB2, TNFRSF13C, IL18, HLA-
DRB1, TLR5, TGFB1, PRTN3, FCER1G, 
HLA-DOB,CD86,TNF 
Role of IL-17A in Psoriasis 1.82E00 S100A7,IL17RC,S100A8,CXCL1,CXCL5DE
FB4A/DEFB4B 
T Helper Cell Differentiation 1.82E00 IL2RG,HLA-DOA, IL12RB1, IL6, BCL6, 
TBX21, IL18,HLA-DRB1, TGFB1, ICOS, 
FCER1G,HLA-DOB,CD86,GATA3,TNF 
PKCθ Signaling in T 
Lymphocytes 
1.77E00 HLA-DOA, CD3E, CD4, PIK3R5, NFKB2, 
PIK3R3, FOS, MAP3K10, CD3G, HLA-
DRB1, GRAP2, VAV3, SOS1, MRAS, 
PIK3R6, FCER1G, HLA-DOB, CD86, 
MAP3K8, NFKBIB, MAP3K3 
Actin Nucleation by ARP-
WASP Complex 
1.67E00 RND2, ARPC5L, RHOC, ITGA2, WASF1, 
NCK2, RHOV, ITGA3, PPP1R12B, WAS, 
SOS1, RHOU, MRAS 
Role of NFAT in Regulation 
of the Immune Response 
1.66E00 HLA-DOA, PLCB2, CD3E, CD4, GNA11, 
PIK3R5, GNG13, FCGR2B,      HLA-DRB1 
GNB3, GNA15, SOS1, MRAS, NFKBIB, 
CD79B, GNAI1, CD79A, GNAZ, NFKB2 
,PIK3R3, CD3G, FOS, MEF2D, FCER1G, 
PIK3R6, CD86, HLA-DOB 
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Small Cell Lung Cancer 
Signaling 
1.66E00 TP53, NOS1, FHIT, PIK3R5, CDK4, 
NFKB2, BCL2, MYC, PIK3R3, PIK3R6, 
PTGS2, NFKBIB, RXRB, CDK2, TRAF1 
Reelin Signaling in Neurons 1.65E00 APOE,ARHGEF15,ITGA2,PIK3R5,ARHGE
F1,MAPK12, DAB1, ITGAL, ITGB3, 
PIK3R3, ITGB2, MAP3K10, ITGA3, 
CNR2,PIK3R6,MAP4K1 
Graft-versus-Host Disease 
Signaling 
1.65E00 PRF1,IL18,HLA-DOA,HLA-DRB1, 
GZMB,FCER1G,CD86,HLA-DOB, IL1F10, 
IL6, TNF 
Dendritic Cell Maturation 1.63E00 B2M,HLA-DOA, PLCB2, IL32, PIK3R5, 
IL6, IL1F10, IGHG1, FCGR2B, CD1D, 
HLA-DRB1,CD1A,FSCN2,LY75,NFKBIB, 
COL2A1, NFKB2, MAPK12, PIK3R3, 
COL1A1,  IL18, PIK3R6, FCER1G, HLA-
DOB, CD86,TNF, CCR7 
NF-κB Activation by Viruses 1.63E00 CCR5, CD4, ITGA2, PIK3R5, NFKB2, 
ITGAL, ITGB3, PIK3R3, ITGB2, ITGA3, 
PIK3R6, MRAS, NFKBIB, PRKD1,CR2 
HGF Signaling 1.63E00 ITGA2, PIK3R5, IL6, MAPK12, MET, 
PIK3R3, FOS, MAP3K10, ITGA3, SOS1, 
PIK3R6, MRAS, MAP3K8, PTGS2, ELF5, 
MAP3K3, ELK3, PRKD1,CDK2 
Crosstalk between Dendritic 
Cells and Natural Killer Cells 
1.61E00 KIR3DL1, IL2RG, KIR2DL2, NCR3, IL6, 
NFKB2, ITGAL, CSF2RB, PRF1, IL18, 
HLA-DRB1, FSCN2, CD226, CD86, 
KIR2DL4, TNF,  CCR7 
MSP-RON Signaling Pathway 1.59E00 PIK3R3, CSF2RB, ITGB2, F12, KLK3, 
PIK3R6, PIK3R5 ,MST1 ,MST1R, CCR2, 
TNF 
Sertoli Cell-Sertoli Cell 
Junction Signaling 
1.57E00 NOS1, SPTBN1, CLDN11 ,CLDN7, 
TUBB2B, MAP3K10, ITGA3 ,CLDN4, 
CGN, MRAS, TUBB4A, JUP, CLDN9, 
CLDN10, GUCY1A3, TJP1, ITGA2, YBX3, 
MAPK12, CLDN5, WAS, MAP3K8, 
ACTN4, A2M, MAP3K3, TNF, CLDN3 
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Eicosanoid Signaling 1.5E00 ALOX15B, PLA2G4D, PTGIR, DPEP3, 
LTB4R2, PTGDR, ABHD3, TBXA2R, 
ALOX12, PTGS2, PTGDS, TBXAS1, 
PLA2G2A 
Integrin Signaling 1.5E00 MYLK2, PIK3R5, ITGB3, NCK2, PARVB, 
ITGA3, PPP1R12B, ITGA11, SOS1, RHOU, 
MRAS, ITGB4, RND2, CAPN6, RHOC, 
ARPC5L, ITGA2, RALB, BCAR3, ITGAL, 
PIK3R3, MYL9, CAPN8, ITGB2, RHOV, 
WAS, PIK3R6, ACTN4, CTTN 
Allograft Rejection Signaling 1.5E00 B2M, PRF1, HLA-DOA, HLA-DQB2, HLA-
DRB1, GZMB, FCER1G, CD86, HLA-DOB, 
IGHG1,TNF 
Acute Phase Response 
Signaling 
1.5E00 FN1, C9, SERPINA3, IL1F10, IL6, RBP1, 
C1RSOS1, MRAS, OSMR, SERPINA1, 
NFKBIB, AGT, SERPINF1, NFKB2, 
MAPK12, SAA4, SERPINF2, PIK3R3, FOS, 
ALB, IL18, HP, A2M, TNF, RBP4 
Granzyme A Signaling 1.49E00 GZMA, HIST1H1A, PRF1, HIST1H1E, 
HIST1H1D, H1F0 
PEDF Signaling 1.48E00 TP53, PPARG, GDNF, SERPINF1, PIK3R5, 
NFKB2, MAPK12, BCL2, PIK3R3, PIK3R6, 
MRAS, DOCK3, NFKBIB, CASP8 
Production of Nitric Oxide 
and Reactive Oxygen Species 
in Macrophages 
1.48E00 APOE PIK3R5, MAP3K10, HOXA10, 
RHOU, SERPINA1 ,S100A8, NFKBIB, 
PRKD1, RND2, RHOC, PPP1R14A, NFKB2, 
MAPK12, SAA4, PIK3R3, FOS, ALB, 
RHOV, CAT, NCF2, PIK3R6, MAP3K8, 
MAP3K3,TNF, RBP4APOC3 
Regulation of Actin-based 
Motility by Rho 
1.48E00 RND2, PFN1, CFL1, RHOC, ARPC5L, 
ITGA2, WASF1, LIMK1, MYL9, RHOV, 
ITGA3, PPP1R12B, WAS, PIP5K1C ,RHOU, 
PIP5KL1 
TGF-β Signaling 1.48E00 FOXH1, SKI, SMAD6, ACVR1 ,INHBC, 
MAPK12, INHBB, ACVR1B, BCL2, FOS, 
PIAS4, AMH, TGFB1, SOS1, MRAS, 
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MAP4K1 
IL-17A Signaling in Airway 
Cells 
1.48E00 PIK3R3, PIK3R6, PIK3R5,MUC5AC, 
IL17RC, MUC5B, CXCL1, IL6, NFKB2, 
CXCL5, NFKBIB, MAPK12, 
DEFB4A/DEFB4B  
Glioma Invasiveness 
Signaling 
1.47E00 RND2, PIK3R3, TIMP3, RHOV, TIMP4, 
RHOC, PIK3R6, MRAS, PIK3R5, RHOU, 
PLAU, ITGB3 
RhoGDI Signaling 1.46E00 GNA11, GNG13, ARHGEF1, LIMK1, 
ITGA3, CDH7, PPP1R12B, GNB3, GNA15, 
RHOU, MRAS, PIP5KL1, CDH13, RND2, 
CFL1, ARPC5L, RHOC, ARHGEF15, 
ITGA2, GNAI1, WASF1, GNAZ, MYL9, 
DGKZ, RHOV, PIP5K1C 
Ephrin B Signaling 1.44E00 EPHB4, RGS3, CFL1, GNA11, GNAI1, 
GNG13, GNAZ, LIMK1, NCK2, EFNB2, 
GNB3, GNA15, VAV3, MRAS 
Germ Cell-Sertoli Cell 
Junction Signaling 
1.43E00 RND2, CFL1, RHOC, TJP1, ITGA2, 
PIK3R5, MAPK12, TUBB2B, LIMK1, 
PIK3R3, MAP3K10, RHOV, ITGA3, 
TGFB1, MRAS, PIK3R6, RHOU, MAP3K8, 
TUBB4A, JUP, ACTN4, TNF, MAP3K3, 
A2M 
IL-8 Signaling 1.42E00 PLCB2, PIK3R5, GNG13, ITGB3, LIMK1, 
BCL2, GNB3 ,RHOU, MRAS, CXCL1, 
NFKBIB, PRKD1, CR2, RND2, RHOC 
,GNAI1, IRAK3, MAPK12, AZU1, PIK3R3, 
MYL9, ITGB2, FOS, RHOV, NCF2, 
PIK3R6, PTGS2 
Agranulocyte Adhesion and 
Diapedesis 
1.41E00 CLDN11 ,SELL, FN1, IL1F10, CXCL5, 
CLDN7ITGA3, CLDN4, CCL3L3, CXCL1, 
CLDN9, CLDN10, C5AR1, MMP28, ITGA2, 
GNAI1, MYL9, ITGB2, CXCL16, IL18, 
CLDN5, CCL4, CXCL2, CX3CL1, TNF, 
CLDN3 
Communication between 
Innate and Adaptive Immune 
1.41E00 B2M, CD4, IL1F10, IGHG1, IL6, 
TNFRSF13C, IL18,HLA-DRB1, CCL4, 
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Cells TLR5, CCL3L3, FCER1G, CD86, TNF, 
CCR7 
Cytotoxic T Lymphocyte-
mediated Apoptosis of Target 
Cells 
1.41E00 B2M, CD3G, PRF1, CD3E, GZMB, 
FCER1G, CASP8,  BCL2 
CCR5 Signaling in 
Macrophages 
1.4E00 FOS,CD3G,CCR5,CCL4,GNB3,CD3E, 
CD4,FCER1G, MRAS, GNAI1, GNG13, 
MAPK12,PRKD1 
FXR/RXR Activation 1.36E00 PPARG,APOE,ABCG5,CYP27A1, NR1H4 
C9, SERPINF1, IL1F10, SAA4, MAPK12, 
SERPINF2, HPR, ALB, IL18, FABP6, 
SERPINA1, TNF, RBP4, AGT, APOC3 
Thrombin Signaling 1.35E00 PLCB2, CAMK1, GATA1, GNA11, PIK3R5, 
GNG13, ARHGEF1, PPP1R12B, GNB3, 
GNA15, SOS1, MRAS, RHOU, PRKD1, 
RND2, RHOC, ARHGEF15, GNAI1, GNAZ, 
NFKB2, MAPK12, PIK3R3, MYL9, RHOV, 
ADCY1, PIK3R6, GATA3 
Cholecystokinin/Gastrin-
mediated Signaling 
1.33E00 RND2, PLCB2, RHOC, EPHA4, IL1F10, 
CCKMAPK12,  FOS, RHOV, IL18, MEF2D, 
SOS1, RHO, MRAS, PTGS2, TNF, PRKD1 
 
Table 11(C): HG vs LG 
Ingenuity Canonical 
Pathways 
-log(B-H p-
value) 
Genes 
Acute Phase Response 
Signaling 
3.05E00 ITIH3, TTR, FN1, APOH, AMBP, 
SERPINF1, IL6, SAA4, MAPK12, F2, 
SERPINF2, SERPIND1, PIK3R3, ALB, 
APOA1, ITIH2, TF, SOS1, SERPINA1, 
OSMR, CRABP2, A2M, AGT, RBP4 
FXR/RXR Activation 3.05E00 ABCG5, TTR, APOB, CYP27A1, APOH, 
AMBP, SERPINF1, APOC2, SAA4, 
MAPK12, SERPINF2, CYP8B1, APOL1, 
ALB, APOA1, TF, APOC1, SERPINA1, 
AGT, RBP4 
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Superoxide Radicals 
Degradation 
3.04E00 TYRP1, CAT, NQO1, CYGB, SOD3 
LXR/RXR Activation 2.99E00 ABCG5, TTR, APOB, APOH, AMBP, 
SERPINF1, APOC2, IL6, SAA4, SERPINF2 
,APOL1, ALB, APOA1, TF, APOC1, 
SERPINA1, NCOR1, RBP4, AGT 
Clathrin-mediated 
Endocytosis Signaling 
2.81E00 MYO6, AP2A1 UBB, APOB, PICALM, 
ARPC5L,RAB7A,PIK3R5, APOC2, SAA4, 
F2, VEGFA, APOL1, PIK3R3, ARRB2, 
ALB, APOA1, TF, PIP5K1C, AAK1, 
APOC1, SERPINA1, ITGB4, RBP4 
Coagulation System 1.7E00 SERPINA5, SERPINA1, F7, A2M, 
SERPINF2, F2 ,PLAT ,SERPIND1 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 
1.7E00 VCAM1, FN1, MYH14, IL6, BAX, BCL2, 
COL1A2, COL16A1, VEGFA, COL5A1, 
CXCL3, COL1A1, IGF2, COL6A1, 
COL13A1, TGFB1, MYH3, EDNRA, A2M, 
COL7A1, EGFR, AGT 
Atherosclerosis Signaling 1.7E00 VCAM1, APOB, APOC2, IL6, SAA4, 
PRDX6, APOL1, COL1A2, COL1A1, ALB, 
ALOX15B, APOA1, TGFB1, APOC1, 
SERPINA1, RBP4 
Role of Tissue Factor in 
Cancer 
1.34E00 STAT5A, CFL1, PIK3R5, F7, MAPK12, F2, 
LIMK1, VEGFA, PIK3R3, ARRB2, ITGA3, 
CXCL1 ,CYR61, EGFR 
 
 
 
Table 11(D): NG vs C 
Ingenuity Canonical 
Pathways 
-log(B-H p- 
Value) 
Genes 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 
1.46E00 IL1R2, IL1R1 ,COL9A2, MMP9 
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Condition Regulation of 
expression 
Genes Fold change (from 
GeneSpring 
analysis) 
NG vs C Upregulated MMP9 2.35 
LG vs C Upregulated MAP3K8 2.46 
LG vs C Downregulated TP53 
SOS1 
2.81 
2.62 
HG vs C Upregulated FOS 
IL6 
2.28 
4.06 
HG vs C Downregulated TNF 2.90 
HG vs LG Upregulated EGFR 
VEGFA 
2.44 
2.13 
HG vs LG Downregulated MAPK12 4.09 
 
Table 12: Final list of genes selected for validation 
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Condition 
 
Gene Fold 
change 
from 
GeneSpring 
Fold 
change 
from 
ddPCR 
p-value 
 
Bonferroni 
correction: 
new 0.05 
threshold, 
10 tests 
Result 
(p-value) 
NG vs C 
 
MMP9 +2.35 +6.49 0.0068 0.005 False 
LG vs C 
 
 
 
 
MAP3K8 
 
TP53 
 
SOS1 
 
+2.46 
 
-2.81 
 
-2.62 
+1.61 
 
+2.00 
 
-1.69 
0.00003 
 
0.00007 
 
0.00362 
0.005 
 
0.005 
 
0.005 
True 
 
True 
 
True 
HG vs C 
 
 
 
 
FOS 
 
IL6 
 
TNF 
 
+2.28 
 
+4.06 
 
-2.90 
+3.55 
 
+3.05 
 
+1.60 
0.00853 
 
0.00001 
 
0.00620 
0.005 
 
0.005 
 
0.005 
False 
 
True 
 
False 
HG vs LG 
 
 
 
 
EGFR 
 
VEGFA 
 
MAPK12 
 
+2.44 
 
+2.13 
 
-4.09 
-1.25 
 
+1.36 
 
+1.19 
0.43 
 
0.24 
 
0.27 
0.005 
 
0.005 
 
0.005 
False 
 
False 
 
False 
 
Table 13: List of significant genes after Bonferroni correction 
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CHAPTER 4: DISCUSSION 
 This study has advanced the idea of using blood-based gene expression studies as 
an indicator of neoplastic changes occuring in brain tissue. This idea was based upon the 
sentinel principle and extrapolated to the study of brain tumours. However, in the very 
first study, the sentinel principle was used to identify subjects with an increased risk of 
colorectal cancer compared to normal subjects (74). In this study, we have used the 
sentinel principle not only to identify patients with a glioma but also to differentiate 
between high grade, low grade, non-glioma and control subjects. 
 The unsupervised hierarchical clustering and principal component analysis clearly 
showed that the four groups of subjects clustered into 3 statistically significant groups as 
represented by the ellipses, which showed a distinct directionality in the different groups 
based on similarities in gene expression (see Results Section, Fig.4). The fact that the 
non-glioma and control subjects clustered together and were distinct from the high and 
low grade tumour patients, indicated that the changes in gene expression in blood in these 
2 groups were clearly different from that of the glioma patients indicating specificity of 
expression. This lends further credence to the sentinel principle that substances are 
released from the tumour into the bloodstream (67,68) and may be  distinct for each 
tumour subtype. Although the blood samples in our study were taken from patients after 
presentation to the hospital with neurological symptoms, it is highly likely that these 
substances were released during the early stages of tumour formation (67) and continued 
to persist in blood even as the tumour enlarged based upon the theory and evidence from 
the sentinel principle (67,68,74-76). 
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 The brain, as an immunologically privileged site, is protected by the blood-brain 
barrier which restricts the movement of water soluble molecules by tight junctions (116) 
and a low level of transcytosis (117). The breakdown of the blood-brain barrier in brain 
tumours can be visualized by either freeze fracture electron microscopy (118) or contrast 
enhanced magnetic resonance imaging (MRI) using gadolinium (119). The normal blood-
brain barrier is impermeable to contrast medium but there is a gradual increase in the 
degree of disruption of the blood-brain barrier corresponding to the grade of the tumour. 
WHO grade II tumours show little or no contrast medium enhancement, WHO grade III 
tumours enrich more contrast medium than grade II tumours while WHO grade IV 
tumours (GBM) show the greatest gadolinium enhancement (100). This observation fits 
well with our postulation that substances from the brain are able to cross the blood-brain 
barrier and enter the circulation due to the varying degrees of disruption of the blood-
brain barrier during glioma formation.  
 The differentially expressed genes for the four different conditions were unique, 
but  also  had some commonality. Most of the unique and common genes in the HG and 
LG tumour samples were transcription factors, cytokines, proto-oncogenes, oncogenes, 
growth factors and tumour suppressor genes. These genes are involved in inflammation, 
tumour signalling pathways, glioma formation, tissue necrosis, apoptosis, homeostasis, 
cytoskeletal architecture, maintenance of the extracellular matrix and determination of 
cell fate. Interestingly, there were also a substantial number of genes involved in the 
innate and adaptive immune system suggesting that modulation of the immune system 
plays a critical role in tumour response. In addition, genes known to be involved in the 
pathogenesis of GBM were also upregulated in blood.  These genes included  EGFR, 
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VEGF and IL-6. This evidence implied that some of the changes occurring in the tumour 
tissue may be reflected in blood, suggesting that these substances may be released into 
the circulation through disruption of the blood-brain barrier or through complex 
signalling mechanisms. 
  The canonical pathways for the 4 sets of conditions mirrored to a certain extent 
the differential gene expression pattern. These included pathways involved in the innate 
and adaptive immune response, interleukin, acute phase response, glioma invasiveness, 
NF-κB activation and TGF-β signalling. The latter 3 pathways are also involved in the 
pathogenesis of gliomas. Again, we see much commonality between the signalling 
pathways in tissue and blood taken from glioma patients. One of the reasons for this 
could be the fact that peripheral blood cells share more than eighty percent of the 
transcriptome with 9 different tissue types including brain (67). More importantly, is the 
fact that blood cells express organ specific genes and also genes that are responsive to 
physiological changes and stimuli that were previously thought to be exclusive to certain 
tissue types (67,120). In the pathogenesis and formation of gliomas, these interactions 
between blood and tissue, together with disruption of the blood-brain barrier, could 
possibly explain some of the similarity observed in gene expression between gliomas and 
peripheral blood cells. 
 However, the results have to be viewed with caution too. The canonical pattern is 
calculated based on the activation state of one or more key genes when the pathway is 
activated. It also depends on the causal relationships with each other (activation and 
inhibition edge between the genes based on findings in the literature) to generate activity 
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patterns for the genes and also the end-point function. In the HG vs C pair (Figure 6A), 
there were only 4 pathways that passed the corrected B-H p-value <0.05 as identified by 
IPA. In addition, a z-score could not be assigned to any of these 4 pathways thus no 
prediction could be made about them. However, they may have biological significance as 
the majority of these pathways are involved in the innate and adaptive immune responses 
that are altered in cancer.  
 Another weakness with the IPA is that one gene may be activating and inhibiting 
at the same time, albeit more commonly on different targets in the same pathway. This 
may result in ambiguous data from the 2 conflicting gene expression values. If the target 
were the same, the effects would cancel out if the magnitude of expression were the 
same, if not, the effect with the larger expression would predominate. This would result 
in inaccurate, incomplete and a masked effect on gene expression. 
 The validation of selected genes was done by ddPCR. As mentioned previously, 
these genes were selected because they were known to be involved in signalling 
pathways that played an important role in tumourigenesis including the pathogenesis and 
formation of gliomas. In the selection of 10 genes for validation, 4 of the 10 genes, 
namely TP53, TNF, MAPK12 and EGFR showed fold changes that were reversed to that 
seen in the microarray experiment. TP53, TNF and MAPK12 were downregulated in the 
microarray experiment but upregulated by validation and EGFR was upregulated in the 
microarray experiment but minimally downregulated by validation. The reason for this 
could be multifactorial. Firstly and most importantly, the probes used for the microarray 
experiment are different from the primers used in ddPCR. As genes very commonly have 
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isoforms, it is likely that the primers in ddPCR may be amplifying an isoform of the gene 
resulting in alternative transcripts. These transcripts may have expression levels that are 
different from the parent gene. In addition, there may be a negative feedback loop where 
one transcript inhibits the expression of the alternative transcript of the same gene or vice 
versa. This could result in reversal of expression as seen during ddPCR validation. 
Secondly, we selected GUSB as the housekeeping gene to normalize our ddPCR data. 
Although GUSB showed the least variation with samples compared to TBP and HuPO, it 
might still have shown some variation in gene expression in the tumour samples. This 
could result in reversal of gene expression after validation. Thirdly, microarray analysis is 
generally used to screen large numbers of genes and the possibility arises that there may 
be false positives. Fourthly, human samples have huge technical and biological 
variability and it is likely that the presence of substances such as activators or inhibitors 
within the samples could be contributing to the differences observed. This is because 
ddPCR, being far more sensitive and quantitative, is able to detect the expression of 
genes affected by either inhibitors or activators, that may not be detected by microarray 
analysis. Fifthly, not all samples were used for validation by ddPCR. Only 3 to 6 samples 
were used for each set of conditions and this may have affected the level and pattern of 
gene expression as well. 
 The initial p-values obtained showed that 7 of the 10 genes chosen for validation 
had statistically significant p-values <0.05. The genes with initial p-values >0.05 were 
EGFR, VEGFA and MAPK12. After applying the Bonferroni correction for the p-value, 
only 4 of the 10 genes passed this stringent statistical test. The 4 genes were MAP3K8, 
IL6, SOS1 and TP53. Although the other genes were not considered to be statistically 
 97 
 
significant, they could be clinically significant. In addition, p-values are dependent on 
many factors including sample size, with a larger sample size giving rise to a more 
reliable p-value (121). In our case with a limited sample size, the p-value could vary by 
adding or removing even one value. Thus a larger sample size would definitely add more 
confidence to the p-values that were obtained in our experiments. 
 Besides the confidence needed in p-values to take forward a panel of genes to 
establish a reliable biomarker, other factors are also important. A biomarker for a disease 
has to be highly sensitive and specific. It must also be reliable and reproducible. A 
biomarker should be able to screen individuals in the preclinical stage of the illness, in 
other words it should be able to detect individuals at risk for developing the disease. It 
should also be diagnostic and prognostic, and able to detect changes in the disease state 
after treatment or recurrence of the disease in cases of relapse (122-124). Therefore, do 
gliomas lend themselves to be suitably detected by a blood-based biomarker?  
 In order to answer this question, we need to look at several variables. Firstly, for a 
biomarker to be used as a screening test in the general population, the incidence of the 
disease should not be extremely low as we would need to screen an excessively large 
number of subjects and this would not be cost effective. Gliomas have a low incidence in 
the population, in the range of 2-3 new cases per 100,000 population per year (115). 
However, if we take into account all the genetic syndromes that involve brain tumours in 
known high risk cancer families such as  neurofibromatosis types 1 and 2, von Hippel-
Lindau disease, tuberous sclerosis complex, Li-Fraumeni syndrome and Turcot 
syndrome, although individually rare causes of brain tumours, but collectively could be 
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important and add to the increased incidence of gliomas. Thus in these cases, a simple, 
non-invasive blood test which involves RNA profiling in whole blood, can be used as an 
addition to the more traditional methods of cancer screening and detection, which in these 
syndromes and disease complexes, involves genetic testing.  
 Secondly, most patients with gliomas especially those with primary GBM, present 
to the hospital after a relatively short history of symptoms which commonly includes 
headache, vomiting, seizures, and motor and sensory loss. This was also the case for all 
the high and low grade glioma patients involved in our study. This is because the tumour 
has enlarged to the point that it has compressed on brain structures and affected particular 
regions of the brain involved in specific neurological function. So, it would be reasonable 
to assume that detection of a small tumour which would be far more amenable to 
complete surgical resection, would portend to a better prognosis. No one has shown thus 
far, that patients with a small tumour have a better prognosis simply because the vast 
majority of patients with gliomas, including the patients in our study, present to hospital 
when they have neurological symptoms. At the time of presentation, the tumour is 
relatively large in size and has diffusely invaded into surrounding brain tissue, making 
complete surgical resection and a cure virtually impossible. In addition, small tumours 
are less likely to be diffuse and thus less infiltrative into surrounding brain tissue. In 
many cases, early symptoms of brain tumours are likely to be mild and very non-specific, 
so a means of stratifying patients for further investigations such as MRI, could be 
determined by using a blood-based biomarker. Conversely, if a patient had an MRI for 
some other reason and a suspicious area was detected suggesting a brain tumour, a watch 
and wait approach could be instituted. The patient could be monitored using a blood-
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based biomarker or followed by MRI, although the frequency of initiating such 
investigations may be difficult to determine. Besides using the blood-based biomarker 
panel as a screening tool, we could also observe how the differential expression of genes 
within the panel change in response to treatment or recurrence of the disease. This is an 
area that needs to be explored further in our study. 
 One of the criteria mentioned earlier about a reliable biomarker is the fact that it 
should be able to diagnose patients at the preclinical stage of the illness, in other words it 
should be  able to detect individuals at risk for developing the disease. Recently, a group 
from the Ohio State University, Columbus, Ohio, USA have found changes in certain 
cytokines and other immune system components that are altered within 5 years of a 
patient developing GBM. There were decreased interactions among cytokines, namely 
between IL4 and sIL4RA within 5 years of the patient being diagnosed with a glioma or 
GBM. This weakened signalling indicated that the tumour was beginning to suppress the 
local immune system, thus predisposing the patient to the development of cancer (125). 
In our case, the differential gene expression pattern observed in the high and low grade 
tumour samples, could be used to predict the risk or probability of a person developing a 
glioma based on the sentinel principle. 
 There are limitations to the use of the sentinel principle and that of a blood-based 
biomarker to detect changes in a disease state in another tissue. The main limitation is 
that the blood transcriptome is susceptible to a vast array of changes such as that due to 
tobacco smoke, environmental pollutants and toxins, and to diseases such as 
hypertension, diabetes, cardiovascular disease, ischaemic stroke and asthma (69-72, 126-
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128). Many cancer patients, including the patients in our study, have these comorbidities 
and this could have a confounding effect on the differential gene expression pattern 
observed. In addition, the drawing of blood, temperature and storage conditions can all 
have an effect on gene expression levels of peripheral blood cells. 
 This is a preliminary study to assess the possibility of using a blood-based 
biomarker to differentiate between high grade, low grade, non-glioma and control 
samples and therefore the results must be interpreted with caution. The main drawback of 
this study is the small sample size. In order to take this study forward to a blood-based 
biomarker panel for gliomas, we would need a much larger sample size to give this study 
more power and to obtain more reliable p-values for the genes selected.  
  This study would also need to be validated in an independent data set. The 
purpose of this would be to estimate how accurately our blood-based biomarker (training 
set) will perform in practice. Therefore, the inclusion of a test set would be needed to 
"test" our blood-based biomarker in the training phase to limit problems like overfitting. 
Ultimately, this would give us an insight on how our biomarker panel will perform in an 
independent data set. 
 Finally, the data in this thesis will be freely available. As the sample number, n, in 
this study is small, this will enable those who are interested to verify the results of this 
study, to use the data as a starting point. They may wish to replicate this study using a 
similar or larger sample size. 
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